Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

809 - Liquid Biopsy has a potential to predict the colorectal cancer patients with destiny for recurrence after curative surgery


24 Nov 2018


Poster display - Cocktail


Translational Research

Tumour Site

Colon and Rectal Cancer


Toshiaki Toshima


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


T. Toshima1, A. Nyuya2, U. Umeda1, K. Yasui1, K. Yoshida1, T. Fujiwara1, A. Goel3, T. Nagasaka2

Author affiliations

  • 1 Gastroenterological Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 2 Medical Oncology, Kawasaki Medical School Hospital, 701-0192 - Kurashiki/JP
  • 3 Center For Gastrointestinal Cancer Research; Center For Epigenetics, Cancer Prevention And Cancer Genomics, Baylor Research Institute And Charles A Sammons Cancer Center, Baylor University Medical Center, Gaston Street Dallas, TX/US


Abstract 809


Nowadays, detection of circulating cell-free tumor DNA (cfDNA) in serum is the frontier noninvasive approach. We reported the utility of detection of cancer-specific methylated CpGs from cfDNA for monitoring tumor dynamics during systemic chemotherapies in colorectal cancer (CRC) patients. The purpose of this study was to establish whether our assay can predict patients with risk for recurrence prospectively by analyzing blood obtained before curative surgery.


Methylation status of CpG sites, considered as cancer-specific alteration, and concentration of cfDNA were evaluated from blood plasma obtained before surgical resection. To analyze aberrant cancer-specific methylation, we modified the highly sensitive assay for bisulfite DNA followed by fluorescence-based PCR, as reported previously (Nagasaka T. et al, Analysis of fecal DNA methylation to detect gastrointestinal neoplasia, J Natl Cancer Inst. 2009 Sep 16;101(18):1244--58. doi: 10.1093/jnci/djp265. Epub 2009 Aug 21). This can detect 8 loci of target promoters, therefore the methylation score (MS) could be ranged from 0 to 8 at a given time, and we also evaluated methylation density in a quantitative manner.


Of the 88 CRC patients enrolled, 16, 26, 25, and 21 patients were stage I, II, III, and IV, respectively. Therefore, to examine whether liquid biopsy can predict CRC patients with risk for recurrence, we focused on stage II and III patients. Of the 51 stage II and III patients, 5 patients received neoadjuvant therapies. Thus, a total of 46 stage II and III CRC patients were finally analyzed. Of the 46 CRC patients, during our observation period [median follow-up was 1056 days (range; 343-1401 days)], only three stage III patients experienced recurrences after curative surgery. Mean plasma MS of the patients with recurrence was increased compared with the patients without recurrences (1.11 vs. 0.8, not significant). When we assessed a methylation density, the mean plasma methylation density of the patients with recurrence was 16078 points (95%CI: 3074-29082) whereas that of the patients without recurrence was 6611 points (95%CI: 3704-9519, P = 0.16).


Although the number of the patients who experienced recurrences after curative resection was too small, our circulating cell-free DNA-based assay showed a potential to predict CRC patients with risk for recurrence after curative surgery.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.